Solventum (SOLV) FY2024 10-K Annual Report
Solventum (SOLV) 10-K annual report for fiscal year 2024, filed with SEC EDGAR on Feb 28, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Solventum FY2024 10-K Analysis
Business Overview
- • Core business model pivot implied by separation from 3M Company via Separation and Distribution Agreement dated March 31, 2024
- • Introduction of multiple transition agreements with 3M supporting independent operations post-separation
- • New executive addition: Doug Jones as MedSurg VP Sales US & Canada with compensation ~$525,000
- • Governance updates: Adoption of Recoupment Policy April 1, 2024 and amendments to bylaws in Sept 2024
- • Most notable fact: 2024 marked spin-off from 3M with extensive transition contracts and standalone governance infrastructure established
Management Discussion & Analysis
- • Revenue for fiscal year 2025 not explicitly stated, no YoY dollar change disclosed
- • No specific profitability or operating margin percentages provided
- • No segment performance data or best/worst segment numbers included
- • No cash flow, buybacks, dividends, or capex figures reported
- • Management notes risks from loss of 3M brand and debt burden affecting profitability and future capital allocation
Risk Factors
- • Regulatory/legal risk: Ongoing impact of 3M Spin-Off-related costs, including profit mark-ups on transition service agreements and separation expenses
- • Geopolitical/macroeconomic risk: Foreign currency transaction effects and hedging reduced pre-tax income by approx. $23 million in 2024
- • Operational/supply chain risk: Increased cost of inventory and transition manufacturing agreements with 3M driving product cost increase by 2.0% in 2024
- • Competitive/market disruption risk: MedSurg volume decline in traditional negative pressure wound therapy due to product portfolio shifts and market demand changes
- • Financial/structural risk: $6.9 billion senior notes and $1.5 billion senior term loans issued in early 2024, with $300 million principal prepaid, changing capital structure post-Spin-Off
Solventum FY2024 Key Financial MetricsXBRL
Revenue
$8.3B
▲ +0.7% YoY
Net Income
$479M
▼ -64.4% YoY
Gross Margin
55.6%
▼ -161bp YoY
Operating Margin
12.6%
▼ -809bp YoY
Net Margin
5.8%
▼ -1062bp YoY
ROE
16.2%
▲ +465bp YoY
Total Assets
$14.5B
▲ +3.7% YoY
EPS (Diluted)
$2.76
▼ -64.6% YoY
Operating Cash Flow
$1.2B
▼ -38.1% YoY
Source: XBRL data from Solventum FY2024 10-K filing on SEC EDGAR. All figures in USD.
Other Solventum Annual Reports
Get deeper insights on Solventum
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.